



Hyloris to present at upcoming European investor conferences

Liège, Belgium – 27 October 2020 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), an innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals, is pleased to announce that members of the senior management team will be presenting to institutional investors at the following upcoming virtual conferences:

Bryan Garnier European Healthcare Conference, on 17 November 2020

Jefferies 2020 Global Healthcare Conference, on 18 - 19 November 2020

Berenberg European Healthcare Conference, on 13 - 14 January 2021

All presentations will be made available on the Company website in the Investors section on the day of the respective events: <https://investors.hyloris.com/>

-Ends-

For more information, please contact:

Hyloris Pharmaceuticals

Stijn Van Rompay, CEO

+32 (0)4 346 02 07

contact@hyloris.com

Consilium Strategic Communications

Amber Fennell, Chris Welsh, Taiana De Ruyck Soares

+44 20 3709 5700

hyloris@consilium-comms.com

About Hyloris Pharmaceuticals SA

Based in Liège, Belgium, Hyloris is an early-stage innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals. Hyloris develops proprietary products it believes offer significant advantages compared to currently available alternatives, with the aim to address the underserved medical needs of patients, hospitals, physicians, payors and other stakeholders in the healthcare system. Hyloris' portfolio spans three

areas of focus: IV Cardiovascular, Other Reformulations and Established Market (high-barrier generics). Hyloris currently has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, commercialized through its partner AltaThera, and Maxigesic® IV, a non-opioid analgesic product for the treatment of pain, developed with the Company's partner, AFT Pharmaceuticals. Additionally, Hyloris has 12 product candidates in various stages of development across the Company's wider portfolio. Read more at www.hyloris.com. Hyloris stands for "high yield, lower risk" and relates to the 505(b)(2) regulatory pathway for product approval on which the Issuer focuses, but in no way relates or applies to an investment in the Shares.